- Home
- VMD vs DRTS Comparison
VMD vs DRTS Comparison
Compare VMD & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMD
- DRTS
- Stock Information
- Founded
- VMD 2006
- DRTS 2015
- Country
- VMD United States
- DRTS Israel
- Employees
- VMD N/A
- DRTS N/A
- Industry
- VMD
- DRTS Medical/Dental Instruments
- Sector
- VMD
- DRTS Health Care
- Exchange
- VMD Nasdaq
- DRTS Nasdaq
- Market Cap
- VMD 280.4M
- DRTS 256.2M
- IPO Year
- VMD N/A
- DRTS N/A
- Fundamental
- Price
- VMD $6.94
- DRTS $3.55
- Analyst Decision
- VMD
- DRTS Strong Buy
- Analyst Count
- VMD 0
- DRTS 1
- Target Price
- VMD N/A
- DRTS $9.00
- AVG Volume (30 Days)
- VMD 319.5K
- DRTS 65.1K
- Earning Date
- VMD 08-06-2025
- DRTS 08-11-2025
- Dividend Yield
- VMD N/A
- DRTS N/A
- EPS Growth
- VMD 47.14
- DRTS N/A
- EPS
- VMD 0.34
- DRTS N/A
- Revenue
- VMD $240,884,000.00
- DRTS N/A
- Revenue This Year
- VMD $19.22
- DRTS N/A
- Revenue Next Year
- VMD $17.51
- DRTS N/A
- P/E Ratio
- VMD $20.16
- DRTS N/A
- Revenue Growth
- VMD 17.11
- DRTS N/A
- 52 Week Low
- VMD $5.93
- DRTS $2.11
- 52 Week High
- VMD $9.81
- DRTS $4.39
- Technical
- Relative Strength Index (RSI)
- VMD 50.31
- DRTS 64.31
- Support Level
- VMD $6.81
- DRTS $3.18
- Resistance Level
- VMD $7.46
- DRTS $3.44
- Average True Range (ATR)
- VMD 0.25
- DRTS 0.16
- MACD
- VMD -0.02
- DRTS 0.03
- Stochastic Oscillator
- VMD 30.57
- DRTS 100.00
About VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.